T. A. Andreeva

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Paul Giangrande, T. A. Andreeva, Pratima Chowdary et al. · Thrombosis and Haemostasis · 2016 · 115 citations

Medicine, Hematology, Pharmacotherapy +15

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A

Robert Klamroth, Gregory M. Hayes, T. A. Andreeva et al. · Human Gene Therapy · 2022 · 111 citations · Full text

Medicine, Hematology, Immunology +13

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

Renchi Yang, L. Rusen, H. Beckmann et al. · Journal of Thrombosis and Haemostasis · 2014 · 88 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

W. Kreuz, Carmen Escuriola Ettingshausen, Vladimír Vdovin et al. · Haemophilia · 2015 · 57 citations · Full text

Life Sciences, Hematology, Immunology +11

Recombinant B‐domain‐deleted porcine sequence factor <scp>VIII</scp> (r‐<scp>pFVIII</scp>) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors

Johnny Mahlangu, T. A. Andreeva, Donald E. Macfarlane et al. · Haemophilia · 2016 · 25 citations · Full text

Medicine, Hematology, Pharmacology +17